Clinical trial · Interventional
Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)
A Phase 2 Study of Nivolumab Plus Ipilimumab in Previously Treated Classical Kaposi Sarcoma (CKS)
NCT03219671CI-TRIAL-00036272unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A Phase 2 study of nivolumab plus ipilimumab in previously treated classical Kaposi Sarcoma (CKS)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Classic Kaposi Sarcoma | Classic Kaposi Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ipilimumab | Drug | Ipilimumab | ALIAS |
| Nivolumab | Drug | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- nivolumab plus ipilimumab
- description
- nivolumab 240mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks
- interventionNames
- Drug: Nivolumab
- Drug: Ipilimumab
Primary outcomes (1)
- measure
- ORR
- timeFrame
- 6-months
- description
- overall response rate (ORR)
Secondary outcomes (3)
- measure
- PFS rate
- timeFrame
- 6-months
- description
- 6-months PFS rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed KS * Age \> 18 * ECOG PS \< 2 * At least one prior treatment modality (palliative radiation or chemotherapy) * Measurable disease as defined by RECIST version 1.1 by physical exam and/or PET-CT (previously irradiated lesions should not be counted as target lesions). Exclusion Criteria: * Patients with HIV-related KS or HIV positive serology. * Ongoing immunosuppressive therapy * Active autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
References
Publications (0)
Data not yet available
No reference posted for this study.